Clinical trials: Locally Advanced Esophageal or GE Junction Cancer
Locally Advanced Esophageal or GE Junction Cancer
Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer
The goal of this clinical trial is to learn if hypofractionation of definitive chemoradiotherapy can treat patients with locally advanced esophageal cancer.
- Trial name
- HYROC (NCT07632079)
- Testing
- Hypofractionation, carboplatin + paclitaxel (CP)
- Where
- 7 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Locally Advanced Esophageal or GE Junction Cancer
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
- Trial name
- NCT00561197
- Testing
- AT-101
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ascenta Therapeutics
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals